Clinical Trial Update: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares acalabrutinib to investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Bendamustine (Bendamustine)
• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-29